Edgewise Therapeutics Inc (EWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) has a cash flow conversion efficiency ratio of -0.086x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.54 Million) by net assets ($493.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Edgewise Therapeutics Inc (EWTX) balance sheet quality index to measure how much of total assets are equity-financed.
Edgewise Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Edgewise Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Edgewise Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Edgewise Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edgewise Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huaihe Energy Group Co Ltd
SHG:600575
|
0.013x |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
0.027x |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
0.029x |
|
Shanxi Coal International Energy Group Co Ltd
SHG:600546
|
0.134x |
|
QL Resources Bhd
KLSE:7084
|
0.056x |
|
ENAGAS A.A. ADR1/2/EO150
F:EG40
|
0.014x |
|
Option Care Health Inc
NASDAQ:OPCH
|
0.103x |
|
MiTAC Holdings Corp
TW:3706
|
0.045x |
Annual Cash Flow Conversion Efficiency for Edgewise Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Edgewise Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Edgewise Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $522.26 Million | $-143.82 Million | -0.275x | -15.99% |
| 2024-12-31 | $459.22 Million | $-109.03 Million | -0.237x | +17.67% |
| 2023-12-31 | $318.83 Million | $-91.95 Million | -0.288x | -89.97% |
| 2022-12-31 | $346.72 Million | $-52.63 Million | -0.152x | -24.31% |
| 2021-12-31 | $274.38 Million | $-33.51 Million | -0.122x | -127.89% |
| 2020-12-31 | $-33.42 Million | $-14.63 Million | 0.438x | -19.53% |
| 2019-12-31 | $-16.85 Million | $-9.17 Million | 0.544x | -- |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more